These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity. Purkey HE; Palaninathan SK; Kent KC; Smith C; Safe SH; Sacchettini JC; Kelly JW Chem Biol; 2004 Dec; 11(12):1719-28. PubMed ID: 15610856 [TBL] [Abstract][Full Text] [Related]
3. Modulating inhibitors of transthyretin fibrillogenesis via sulfation: polychlorinated biphenyl sulfates as models. Grimm FA; Lehmler HJ; He X; Robertson LW; Duffel MW Chem Biol Interact; 2015 Feb; 228():1-8. PubMed ID: 25595224 [TBL] [Abstract][Full Text] [Related]
4. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. Johnson SM; Petrassi HM; Palaninathan SK; Mohamedmohaideen NN; Purkey HE; Nichols C; Chiang KP; Walkup T; Sacchettini JC; Sharpless KB; Kelly JW J Med Chem; 2005 Mar; 48(5):1576-87. PubMed ID: 15743199 [TBL] [Abstract][Full Text] [Related]
5. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation. Sato T; Ando Y; Susuki S; Mikami F; Ikemizu S; Nakamura M; Suhr O; Anraku M; Kai T; Suico MA; Shuto T; Mizuguchi M; Yamagata Y; Kai H FEBS Lett; 2006 Jan; 580(2):491-6. PubMed ID: 16386248 [TBL] [Abstract][Full Text] [Related]
6. Synthesis of 4H-1,4-oxazines as transthyretin amyloid fibril inhibitors. Li W; Duan X; Yan H; Xin H Org Biomol Chem; 2013 Jul; 11(27):4546-50. PubMed ID: 23733168 [TBL] [Abstract][Full Text] [Related]
7. Mono-hydroxylated polychlorinated biphenyls are potent aryl hydrocarbon receptor ligands in recombinant yeast cells. Kamata R; Shiraishi F; Nakajima D; Takigami H; Shiraishi H Toxicol In Vitro; 2009 Jun; 23(4):736-43. PubMed ID: 19327395 [TBL] [Abstract][Full Text] [Related]
8. Hydroxylated polychlorinated biphenyls (PCBs) interact with protein disulfide isomerase and inhibit its activity. Okada K; Hashimoto S; Funae Y; Imaoka S Chem Res Toxicol; 2009 May; 22(5):899-904. PubMed ID: 19374345 [TBL] [Abstract][Full Text] [Related]
9. Stability and fibril formation properties of human and fish transthyretin, and of the Escherichia coli transthyretin-related protein. Lundberg E; Olofsson A; Westermark GT; Sauer-Eriksson AE FEBS J; 2009 Apr; 276(7):1999-2011. PubMed ID: 19250316 [TBL] [Abstract][Full Text] [Related]
10. Kinetic stabilization of an oligomeric protein by a single ligand binding event. Wiseman RL; Johnson SM; Kelker MS; Foss T; Wilson IA; Kelly JW J Am Chem Soc; 2005 Apr; 127(15):5540-51. PubMed ID: 15826192 [TBL] [Abstract][Full Text] [Related]
11. Clusterin regulates transthyretin amyloidosis. Lee KW; Lee DH; Son H; Kim YS; Park JY; Roh GS; Kim HJ; Kang SS; Cho GJ; Choi WS Biochem Biophys Res Commun; 2009 Oct; 388(2):256-60. PubMed ID: 19664600 [TBL] [Abstract][Full Text] [Related]
12. Effect of nitric oxide in amyloid fibril formation on transthyretin-related amyloidosis. Saito S; Ando Y; Nakamura M; Ueda M; Kim J; Ishima Y; Akaike T; Otagiri M Biochemistry; 2005 Aug; 44(33):11122-9. PubMed ID: 16101296 [TBL] [Abstract][Full Text] [Related]
13. TTR fibril formation inhibitors: is there a SAR? Nencetti S; Orlandini E Curr Med Chem; 2012; 19(15):2356-79. PubMed ID: 22471984 [TBL] [Abstract][Full Text] [Related]
14. Potential mechanisms of thyroid disruption in humans: interaction of organochlorine compounds with thyroid receptor, transthyretin, and thyroid-binding globulin. Cheek AO; Kow K; Chen J; McLachlan JA Environ Health Perspect; 1999 Apr; 107(4):273-8. PubMed ID: 10090705 [TBL] [Abstract][Full Text] [Related]
15. Transthyretin forms amyloid fibrils at physiological pH with ultrasonication. Misumi Y; Ueda M; Fujimori H; Shinriki S; Meng W; Kim J; Saito S; Obayashi K; Uchino M; Ando Y Amyloid; 2008 Dec; 15(4):234-9. PubMed ID: 19065294 [TBL] [Abstract][Full Text] [Related]
16. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state. Petrassi HM; Johnson SM; Purkey HE; Chiang KP; Walkup T; Jiang X; Powers ET; Kelly JW J Am Chem Soc; 2005 May; 127(18):6662-71. PubMed ID: 15869287 [TBL] [Abstract][Full Text] [Related]
17. Hormone affinity and fibril formation of piscine transthyretin: the role of the N-terminal. Morgado I; Melo EP; Lundberg E; Estrela NL; Sauer-Eriksson AE; Power DM Mol Cell Endocrinol; 2008 Nov; 295(1-2):48-58. PubMed ID: 18620020 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and evaluation of oxazole transthyretin amyloidogenesis inhibitors. Razavi H; Powers ET; Purkey HE; Adamski-Werner SL; Chiang KP; Dendle MT; Kelly JW Bioorg Med Chem Lett; 2005 Feb; 15(4):1075-8. PubMed ID: 15686915 [TBL] [Abstract][Full Text] [Related]
19. Amyloid disease prevention by transthyretin native state complexation with carborane derivatives lacking cyclooxygenase inhibition. Julius RL; Hawthorne MF Drug News Perspect; 2008 Jun; 21(5):258-66. PubMed ID: 18596990 [TBL] [Abstract][Full Text] [Related]
20. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. Oza VB; Smith C; Raman P; Koepf EK; Lashuel HA; Petrassi HM; Chiang KP; Powers ET; Sachettinni J; Kelly JW J Med Chem; 2002 Jan; 45(2):321-32. PubMed ID: 11784137 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]